Madrigal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Madrigal Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. 

CEO
William J. Sibold
CEOWilliam J. Sibold
Employees
915
Employees915
Headquarters
West Conshohocken, Pennsylvania
HeadquartersWest Conshohocken, Pennsylvania
Founded
2000
Founded2000
Employees
915
Employees915

MDGL Key Statistics

Market cap
10.77B
Market cap10.77B
Price-Earnings ratio
-36.51
Price-Earnings ratio-36.51
Dividend yield
Dividend yield
Average volume
274.27K
Average volume274.27K
High today
High today
Low today
Low today
Open price
$486.80
Open price$486.80
Volume
0.00
Volume0.00
52 Week high
$615.00
52 Week high$615.00
52 Week low
$275.00
52 Week low$275.00

Stock Snapshot

The current Madrigal Pharmaceuticals(MDGL) stock price is $475.38, with a market capitalization of 10.77B. The stock trades at a price-to-earnings (P/E) ratio of -36.51.

On 2026-06-09, Madrigal Pharmaceuticals(MDGL) shares started trading at $486.80, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 274.27K.

The stock's 52-week range extends from a low of $275.00 to a high of $615.00.

The stock's 52-week range extends from a low of $275.00 to a high of $615.00.

MDGL News

Simply Wall St 4d
A Look At Madrigal Pharmaceuticals Valuation After New Rezdiffra Data And Analyst Upgrades - simplywall.st

...

A Look At Madrigal Pharmaceuticals Valuation After New Rezdiffra Data And Analyst Upgrades - simplywall.st
Simply Wall St 5d
Madrigal Pharmaceuticals Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?

In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular...

Madrigal Pharmaceuticals Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?

Analyst ratings

89%

of 18 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

People also own

Based on the portfolios of people who own MDGL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.